.
I doubt whether most physicians would consider haemoptysis and pleuritic chest pain as indicating pulmonary infarction. On one medical ward in the last month I have seen three cases of undoubted pneumococcal pneumonia presenting with pleuritic chest pain and haemoptysis.
It has become increasingly clear over recent years that clinical impressions are a very poor judge of therapeutic efficacy in self-limiting disorders, particularly where expectation of benefit is high.
It is clear that clinical expectations of oral anticoagulants, for example, were very high from the outset. In the words of the discoverer of bishydroxycoumarin, Paul Link, after rudimentary studies in animal toxicology, this drug was 'grabbed from his hands by the clinicians'. The curious situation has arisen where, rather than the proponents of anticoagulant therapy having to prove benefits from this treatment, sceptics, like myself, are placed in the impossible situation of having to prove that they donot work.
The issue is clouded somewhat by a semantic confusion. Anticoagulants are undoubtedly effective in preventing clot formation. As long as clinicians talk loosely about 'clots in the lungs', many will feel subconsciously that any formal demonstration of therapeutic benefit is superfluous. However, the structure and composition of a clot in a test tube is very different from that of a thrombus in a vein. The evidence for an anti thrombotic effect of anticoagulants in humans is elusive.
An interesting analogy may be found in the anticoagulant treatment of myocardial infarction (MI). In the days when it was commonly assumed that MI was caused by in situ thrombosis, anticoagulants were in widespread use for this disease and the results of several large trials were even more spectacular than the results reported by Barritt & Jordan (1960) for pulmonary embolism. Gifford & Feinstein (1969) have pointed out that the most impressive results were obtained in the trials with the poorest experimental design. Now that the theory of pathophysiology has changed somewhat, anticoagulants have falIen out of favour in this application.
It is important to emphasize that heparin and warfarin are very dangerous drugs, The mortality of heparin in one prospective trial has been 2%, the morbidity close to 40% (Salzmann et al. 1975) . It is ethicalIy unacceptable to use these drugs in the vague hope that they may be doing some good, or simply because no better treatment is available. Yours sincerely PAULEGERMAYER 30 August 1981
